Investors often gauge the potential direction of a stock by monitoring insider transactions. In the case of Dexcom Inc (NASDAQ: DXCM), recent insider activity has drawn attention as company executives adjusted their holdings amid notable analyst updates.
On September 5, 2025, insider Kyle Malady sold 667 shares of Dexcom Inc at $80.86 per share, totaling $53,934 in proceeds. Following this transaction, Malady’s holdings declined to 22,667 shares, currently valued at approximately $1.32 million. Interestingly, this sale came after Malady had purchased 667 shares at the same price in a prior trade valued at $53,934, suggesting a short-term position adjustment.
Meanwhile, Sadie Stern also executed a sale, disposing of 1,466 shares at $80.00 each, for total proceeds exceeding $117,280. After this transaction, Stern retains 105,223 shares in the company.
Analyst Actions on Dexcom Inc
In early September 2025, Oppenheimer downgraded Dexcom Inc from an “Outperform” to a “Perform” rating, signaling a more cautious stance. However, Argus initiated coverage on August 21, 2025, with a “Buy” recommendation, while Truist also began coverage earlier on June 16, 2025, echoing a similar bullish outlook.
Analyzing DXCM Stock Performance
In the most recent trading session, Dexcom Inc [NASDAQ: DXCM] declined -2.13% to close at $58.02. The stock traded between $56.89 and $60.00 during the session. Over the past five days, DXCM shares have dropped approximately -14.93%, and are down -16.76% year-to-date.
The stock’s 52-week range shows a high of $93.25 (February 18, 2025) and a low of $56.44 (October 31, 2025).
Support and Resistance Levels
Based on the 24-hour chart, support for DXCM lies at $56.61, with a potential secondary level at $55.19 if the first is breached. On the upside, resistance levels are set at $59.72 and $61.41. The Relative Strength Index (RSI) currently stands at 29.98, indicating the stock is in oversold territory, which may suggest a possible rebound if buying interest returns.
Short Interest Trends
As of October 15, 2025, short interest in Dexcom Inc fell by 1.52 million shares, totaling 11.62 million, down from 13.14 million on September 15, 2025. This -13.13% decline signals a slight improvement in market sentiment. Short shares currently account for 1.84% of the float, with a days-to-cover ratio of 1.84.
Institutional and Analyst Outlook
According to FactSet data, analysts project an average 12-month price target of $84.50 for DXCM, representing an upside potential of approximately 42.54% from the recent closing price of $59.28. Forecasts range from a low of $75 to a high of $99.
At the end of 2025, 12 analysts rated Dexcom Inc as a “Buy.” Additionally, on May 30, 2025, Goldman Sachs initiated coverage on the stock with a “Buy” rating and a $104 price target, reflecting long-term optimism despite recent volatility.
Overall, insider selling and analyst downgrades have tempered short-term sentiment around Dexcom Inc (NASDAQ: DXCM), but long-term projections and reduced short interest suggest that market confidence remains cautiously optimistic.